🔗 Share this article The Global Health Body Raises Warning Over Acute Shortage of Obesity Jabs Fewer than a tenth of people who could benefit from weight-loss injections such as Wegovy can access them, caution the WHO as it publishes its inaugural advice on the medications. With in excess of 1,000,000,000 people worldwide currently obese, it is calling for broader and more equitable availability to these injectable treatments. Per projections, over two billion could be obese by 2030 without intervention. "The new guidance affirms that obesity is a lifelong illness that can be managed with holistic and lifelong care," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are key obstacles to universal availability to the treatments that can assist patients in reducing significant weight, says the body. Weight-Loss Drug Scarcity Even under the present most optimistic scenario, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of those who need them, according to the health organization. The guideline encourages nations and manufacturers to widen availability, by strategies like voluntary licensing. Exclusive production rights on a key compound – the main component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026. The Way Weight-Loss Drugs Work The injections replicate a natural hormone to reduce digestion speed, curb appetite and boost the sense of being full so users eat less. People typically start to lose weight after several weeks of commencing the weekly injections. Studies indicates users may regain a significant portion a year later of stopping the treatment, as their typical hunger resume. To be overweight or obese elevates your likelihood for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and specific cancers. Obesity impacts people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, per the WHO.
Fewer than a tenth of people who could benefit from weight-loss injections such as Wegovy can access them, caution the WHO as it publishes its inaugural advice on the medications. With in excess of 1,000,000,000 people worldwide currently obese, it is calling for broader and more equitable availability to these injectable treatments. Per projections, over two billion could be obese by 2030 without intervention. "The new guidance affirms that obesity is a lifelong illness that can be managed with holistic and lifelong care," stated its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are key obstacles to universal availability to the treatments that can assist patients in reducing significant weight, says the body. Weight-Loss Drug Scarcity Even under the present most optimistic scenario, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of those who need them, according to the health organization. The guideline encourages nations and manufacturers to widen availability, by strategies like voluntary licensing. Exclusive production rights on a key compound – the main component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026. The Way Weight-Loss Drugs Work The injections replicate a natural hormone to reduce digestion speed, curb appetite and boost the sense of being full so users eat less. People typically start to lose weight after several weeks of commencing the weekly injections. Studies indicates users may regain a significant portion a year later of stopping the treatment, as their typical hunger resume. To be overweight or obese elevates your likelihood for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and specific cancers. Obesity impacts people in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, per the WHO.